目录
- PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
- Tumor immune microenvironment characterization and response to anti-PD-1 therapy
- Understanding the function and dysfunction of the immune system in lung cancer: the role of immune checkpoints
- Assays for predicting and monitoring responses to lung cancer immunotherapy
- Current approaches in treatment of triple-negative breast cancer
- Changes in tumor-antigen expression profile as human small-cell lung cancers progress
- Predictive value of K-ras and PIK3CA in non-small cell lung cancer patients treated with EGFR-TKIs: a systemic review and meta-analysis
- Paclitaxel-etoposide-carboplatin/cisplatin versus etoposidecarboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases